From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices

摘要

Purpose: To quantify rheumatology patient preferences and willingness to pay (WTP) for features differentiating enhanced from standard self-injection devices and to investigate differences among subgroups. Patients and methods: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) were recruited in the UK. A discrete-choice experiment was used to elicit preferences; respondents were presented with 10 choices between 3 different devices: a free standard disposable device, and 2 hypothetical reusable devices characterized by presence/absence of skin sensor, injection speed control, on-screen instructions, injection reminders, electronic log, and large grip. Every hypothetical device included a cost component to assess WTP for each enhanced feature. A random-parameters logit model was used to estimate preference weights and WTP. Results: Data were collected from 323 respondents by electronic survey (15/11/2017–15/02/2018; RA: 108; PsA: 103; axSpA: 112). On average, the skin sensor was the most preferred feature (￡30), followed by injection speed control, injection reminders, electronic log (～￡20 each), on-screen instructions (～￡12), and a device with a small, rather than large grip (～￡7). Similar preferences for attributes were observed across condition subgroups except for grip size: axSpA patients preferred small grip (～￡27); PsA patients preferred large grip (～￡19). Overall, respondents preferred reusable devices with all enhanced features (WTP value: ￡85) over the standard device. RA patients exhibited a higher WTP (￡145) than PsA (￡102) or axSpA (￡62) for the same enhanced device. Conclusion: Patients positively valued reusable self-injection devices with enhanced features, which may improve patient experience, potentially improving treatment adherence, clinical, and economic outcomes.